Astellas Takes First Steps In India With Prograf
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Astellas Pharma said April 12 that its Indian subsidiary has commenced marketing immunosuppressant Prograf (tacrolimus), its flagship product, in India, in the company's first stab at the world's second most populous country
You may also be interested in...
Fierce Generic Competition Leads Astellas Into Tier-Based Pricing For Prograf In India
MUMBAI - Seventeen years after Prograf (tacrolimus) was first introduced into the market, Japan's second largest drug maker, Astellas Pharma, is still counting heavily on its blockbuster transplant drug to push future growth
Fierce Generic Competition Leads Astellas Into Tier-Based Pricing For Prograf In India
MUMBAI - Seventeen years after Prograf (tacrolimus) was first introduced into the market, Japan's second largest drug maker, Astellas Pharma, is still counting heavily on its blockbuster transplant drug to push future growth
Fierce Generic Competition Leads Astellas Into Tier-Based Pricing For Prograf In India
The Indian market for transplant products is pegged at $36 million and is expected to grow in double digits.